
Regeneron Pharmaceuticals, Inc.
REGNAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Nov 2, 2026 | Cantor Fitzgerald | Carter Gould | $980.00(+2%) | $962.36 | StreetInsider |
| Nov 2, 2026 | Wells Fargo | $1030.00(+11%) | $927.89 | StreetInsider | |
| Nov 2, 2026 | Guggenheim | Yatin Suneja | $1100.00(+19%) | $927.89 | StreetInsider |
| Nov 2, 2026 | Wells Fargo | Mohit Bansal | $925.00(-0%) | $927.89 | StreetInsider |
| Oct 30, 2026 | Robert W. Baird | Brian Skorney | $875.00(-6%) | $927.89 | StreetInsider |
| Oct 19, 2026 | Piper Sandler | $865.00(+9%) | $790.74 | TheFly | |
| Oct 14, 2026 | UBS | $978.00(+26%) | $778.36 | TheFly | |
| Oct 8, 2026 | RBC Capital | Brian Abrahams | $810.00(+11%) | $730.08 | TheFly |
| Oct 8, 2026 | Raymond James | Chris Raymond | $911.00(+23%) | $742.12 | StreetInsider |
| Oct 7, 2026 | Truist Financial | $780.00(+4%) | $747.51 | TheFly | |
| Oct 7, 2026 | Morgan Stanley | $779.00(+5%) | $743.60 | TheFly | |
| Oct 1, 2026 | Jefferies | $930.00(+25%) | $741.16 | TheFly | |
| Oct 1, 2026 | BMO Capital | Evan David Seigerman | $920.00(+24%) | $741.41 | StreetInsider |
| Oct 1, 2026 | Argus Research | $850.00(+12%) | $758.27 | TheFly | |
| Sep 10, 2026 | HSBC | Rajesh Kumar | $920.00(+14%) | $807.65 | TheFly |
| Aug 17, 2026 | Leerink Partners | David Risinger | $824.00(+3%) | $803.48 | TheFly |
| Aug 14, 2026 | Bernstein | Jeffrey Walch | $756.00(-5%) | $799.46 | StreetInsider |
| Aug 3, 2026 | Guggenheim | $1030.00(+35%) | $763.51 | TheFly | |
| Jul 31, 2026 | RBC Capital | $737.00(-0%) | $739.50 | TheFly | |
| Jul 31, 2026 | Morgan Stanley | $758.00(+3%) | $738.82 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| B of A Securities | maintain | Buy | Nov 2, 2026 |
| Leerink Partners | maintain | Market Perform | Nov 2, 2026 |
| Bernstein | maintain | Market Perform | Nov 2, 2026 |
| Morgan Stanley | maintain | Equal Weight | Nov 2, 2026 |
| Truist Securities | maintain | Buy | Nov 2, 2026 |
| RBC Capital | maintain | Sector Perform | Nov 2, 2026 |
| Guggenheim | maintain | Buy | Nov 2, 2026 |
| Wells Fargo | maintain | Equal Weight | Nov 2, 2026 |
| Evercore ISI Group | maintain | Outperform | Nov 2, 2026 |
| Canaccord Genuity | maintain | Buy | Nov 2, 2026 |
| Cantor Fitzgerald | maintain | Overweight | Nov 2, 2026 |
| Baird | maintain | Neutral | Nov 2, 2026 |
| Citigroup | maintain | Neutral | Oct 30, 2026 |
| JP Morgan | maintain | Overweight | Oct 30, 2026 |
| Canaccord Genuity | maintain | Buy | Oct 28, 2026 |
| TD Cowen | maintain | Buy | Oct 21, 2026 |
| Piper Sandler | maintain | Overweight | Oct 19, 2026 |
| UBS | upgrade | Neutral →Buy | Oct 15, 2026 |
| RBC Capital | maintain | Sector Perform | Oct 8, 2026 |
| Morgan Stanley | maintain | Equal Weight | Oct 7, 2026 |
| Truist Securities | maintain | Buy | Oct 7, 2026 |
| JP Morgan | maintain | Overweight | Oct 6, 2026 |
| Argus Research | upgrade | Hold →Buy | Oct 1, 2026 |
| Jefferies | maintain | Buy | Oct 1, 2026 |
| RBC Capital | maintain | Sector Perform | Sep 29, 2026 |
Earnings History
Next report: Jan 28, 2027 · EPS est. $25.39| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Oct 30, 2026 | $20.07 | $16.51 | $5.12B | $4.58B |
| Jul 30, 2026 | $14.29 | $10.16 | $4.29B | $3.82B |
| Apr 29, 2026 | $9.47 | $8.91 | $3.61B | $3.48B |
| Jan 30, 2026 | $11.44 | $10.74 | $3.88B | $3.81B |
| Oct 28, 2025 | $11.83 | $9.65 | $3.75B | $3.59B |
| Aug 1, 2025 | $12.89 | $8.43 | $3.68B | $3.29B |
| Apr 29, 2025 | $8.22 | $8.62 | $3.03B | $3.25B |
| Feb 4, 2025 | $12.07 | $11.21 | $3.79B | $3.74B |
News
These are among the best the industry has to offer.
Single administration of CIDEB siRNA resulted in rapid, deep and durable reductions in liver fat by up to 80% that were sustained through 36 weeks
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN - Get Free Report) Director Huda Zoghbi sold 7,439 shares of the firm's stock in a transaction on Tuesday, November 3rd. The stock was sold at an average price of $970.46, for a total value of $7,219,251.94. Following the completion of the transaction, the director owned 1,703 shares in the company,
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN - Get Free Report) EVP Joseph Larosa sold 4,466 shares of the firm's stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $965.49, for a total transaction of $4,311,878.34. Following the completion of the transaction, the executive vice president owned 38,906 shares of
Compass Financial Management LLC grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 4,526.2% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,007 shares of the biopharmaceutical company's stock after acquiring an additional 2,942 shares during the
AIA Group Ltd cut its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 37.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 5,482 shares of the biopharmaceutical company's stock after selling 3,254 shares during the period. AIA Group Ltd's holdings
Bank Julius Baer and Co. Ltd Zurich boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 165.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,904 shares of the biopharmaceutical company's stock after
Regeneron (REGN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Regeneron (REGN) and Illumina (ILMN). But which of these two stocks presents investors with the better value opportunity right now?
On CNBC's “Halftime Report Final Trades,” Jim Lebenthal, partner and chief market strategist at Cerity Partners, picked Cleveland-Cliffs Inc. (NYSE:CLF).
International Assets Investment Management LLC grew its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 356.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,573 shares of the biopharmaceutical company's stock after purchasing an additional 3,572 shares during the period.
TARRYTOWN, N.Y., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: 2026 Jefferies Global Healthcare Conference in London at 2:00 p.m.
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) on Friday reported better-than-expected third-quarter 2026 results. Regeneron reported adjusted earnings of $20.07 per share, up 70% year over year and above the analyst consensus estimate of $16.19.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Regeneron Pharmaceuticals (NASDAQ: REGN - Get Free Report) and Syndax Pharmaceuticals (NASDAQ: SNDX - Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation. Earnings and Valuation This table compares Regeneron Pharmaceuticals
Dupixent global quarterly net sales grew 35% year over year to $6.5 billion. Total revenue increased 36% year over year to $5.1 billion.
Regeneron's Q3 earnings and revenues beat estimates, fueled by strong Dupixent profits, Eylea HD growth and robust Libtayo demand. Stock up.
Regeneron Pharmaceuticals, Inc. (REGN) Q3 2026 Earnings Call Transcript
Regeneron delivered a standout Q3, with net sales up 36% year-over-year to $5.1 billion, driven mainly by Dupixent's outperformance. Eylea HD and Libtayo posted strong growth, while Eylea 2 mg showed resilience despite biosimilar competition; pipeline updates further reinforced Regeneron's momentum. I now expect 2026 revenues to reach $19 billion, a 33% increase, and non-GAAP EPS growth in the low- to mid-50% range.
Regeneron Pharmaceuticals NASDAQ: REGN reported third-quarter 2026 revenue growth of 36% year over year to $5.1 billion, while non-GAAP diluted earnings per share rose 70% to $20.07. The company attributed the performance to increased Sanofi collaboration revenue and continued growth from DUPIXENT, EYLEA HD and LIBTAYO.